Commentary by Doreen Addrizzo-Harris MD, Associate Professor, Division of Pulmonary and Critical Care Medicine
The 2007 American Thoracic Society (ATS) meeting took place between May18-23 in San Francisco, California at the Moscone Conference center. There were more than 400 …
Much of the week in the media was spent discussing XDR TB. Andrew Speaker, a man on his way to his wedding in Santorini Greece (the picture of his wedding is to the right) managed to evade US security multiple times. …
Commentary by Mitchell Charap, MD Senior Associate Program Director, NYU Internal Medicine Residency Program
I now return (See previous post) to my discussion of the STAR *D report (Am J Psychiatry. 2006;106) which is a very …
Commentary by Michael Seidman MD, Chief Oncology Fellow
New treatment options for both early and advanced Renal Cell Cancer have recently been published. Traditionally, treatment for early stage disease was partial or radical nephrectomy. In the …
Commentary by Dr. Daniel Labovitz, Director of the NYU Stroke Center
After an 8-year hiatus, the American Heart Association/American Stroke Association has at last published a fresh set of guidelines on the management of acute spontaneous intracerebral hemorrhage (ICH) …
The big bomb this past week was the Rosiglitazone Effect. Resulting in front page news in various newspapers (on multiple days), the meta-analysis in last week’s NEJM is causing quite the stir. For more information, …
A 31 year old female with hypertension and proteinuria secondary to IgA nephropathy, currently treated with an ARB, presents to clinic stating that she would like to become pregnant.
What is the risk of fetal morbidity in the …
Back in December we reported on the FDA cautioning practioners about the use of gadolinium (an mri contrast agent) in patients with chronic kidney disease.  The FDA is now requesting a black box warning  stating “that patients with severe kidney insufficiency who receive gadolinium-based agents are at risk for developing a debilitating, …